Table 2 |
|||||||
|
Type of prescription based on GI risk and CV history |
|||||||
|
Prescription |
Low GI risk |
Mod. GI risk |
High GI risk |
P** value |
|||
|
|
|||||||
|
No CV Hx* |
CV Hx |
No CV Hx |
CV Hx |
No CV Hx |
CV Hx |
||
|
N (%) |
N (%) |
N (%) |
N (%) |
N (%) |
N (%) |
||
|
N = 1,144 |
N = 62 |
N = 4,373 |
N = 871 |
N = 5,697 |
N = 4,323 |
||
|
SYSADOA |
52 (4.6) |
0 (0.0) |
92 (2.1) |
22 (2.5) |
44 (0.8) |
33 (0.8) |
<0.0001 |
|
Paracetamol |
108 (9.4) |
13 (21.0) |
391 (8.9) |
121 (13.9) |
331 (5.8) |
480 (11.1) |
<0.0001 |
|
Opioids |
11 (1.0) |
1 (1.6) |
40 (0.9) |
11 (1.3) |
28 (0.5) |
28 (0.7) |
0.03 |
|
Combinations of any of the 3* |
72 (6.2) |
5 (8.0) |
306 (7.0) |
97 (11.1) |
498 (8.7) |
586 (13.5) |
<0.0001 |
|
nsNSAIDs |
554 (48.4) |
27 (43.5) |
2,091 (47.8) |
353 (40.5) |
2,807 (49.3) |
1,789 (41.4) |
<0.0001 |
|
nsNSAID+ GP*** |
307/554 (55.4) |
18/27 (66.7) |
1,687/2,091 (80.7) |
302/353 (85.6) |
2,552/2,807 (90.9) |
1,691/1,789 (94.5) |
<0.0001 |
|
Cox-2 NSAID |
267 (23.3) |
13 (21.0) |
1,335 (30.5) |
227 (26.1) |
2,154 (37.8) |
1,428 (33.0) |
<0.0001 |
|
Cox-2 + GP*** |
89/267 (33.3) |
4/13 (30.8) |
694/1,335 (52.0) |
149/227 (65.6) |
1,554/2,154 (72.1) |
1,177/1,428 (82.4) |
<0.0001 |
|
|
|||||||
|
CV HX = cardiovascular history; GP = gastroprotectant (>91% PPI). * Sysadoa, paracetamol, opioids; ** P-values denotes differences among groups overall; *** nsNSAIDS + GP data express the number of patients and % of patients with nsNSAIDs prescription that also take a gastroprotective agent. Also, COX-2 + GP data express the number of patients and % of patients with COX-2 selective inhibitors prescriptions that also take a gastroprotective agent. |
|||||||
|
Lanas et al. BMC Medicine 2011 9:38 doi:10.1186/1741-7015-9-38 |
|||||||
